Abivax Announces Pricing of Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares

  • Upsized offering increased from the previously announced $600M to $800M at $125.00 per ADS, priced at a 2.39% premium to the three-day VWAP
  • Expected gross proceeds of approximately $800M (€702M), before potential exercise of the Underwriters’ Option, are anticipated to extend the Company's cash runway into Q2 2029, supporting potential commercialization of obefazimod and continued clinical development

PARIS, France, July 1, 2026 – 2:30 p.m. (CEST) – Abivax SA (PARIS:FR, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announces the pricing of its previously announced underwritten public offering of 6,400,000 American Depositary Shares ("ADSs"), each representing one ordinary share, €0.01 nominal value per share (each an "Ordinary Share"), of the Company, in the United States at an offering price of $125.00 per ADS (the "Offering"). The size of the ADS Offering was increased from the previously announced offering size of $600.0 million ADSs.